116 related articles for article (PubMed ID: 34263472)
1. Assessing the ability of boys with Duchenne muscular dystrophy age 4-7 years to swallow softgel capsules: Clinical trial experience with edasalonexent.
Mancini M; Shafai G; Thaler E; Donovan JM; Finkel RS
J Clin Pharm Ther; 2022 Jan; 47(1):33-37. PubMed ID: 34263472
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial.
Finkel RS; McDonald CM; Lee Sweeney H; Finanger E; Neil Knierbein E; Wagner KR; Mathews KD; Marks W; Statland J; Nance J; McMillan HJ; McCullagh G; Tian C; Ryan MM; O'Rourke D; Müller-Felber W; Tulinius M; Burnette WB; Nguyen CT; Vijayakumar K; Johannsen J; Phan HC; Eagle M; MacDougall J; Mancini M; Donovan JM;
J Neuromuscul Dis; 2021; 8(5):769-784. PubMed ID: 34120912
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial.
Finkel RS; Finanger E; Vandenborne K; Sweeney HL; Tennekoon G; Shieh PB; Willcocks R; Walter G; Rooney WD; Forbes SC; Triplett WT; Yum SW; Mancini M; MacDougall J; Fretzen A; Bista P; Nichols A; Donovan JM
Neuromuscul Disord; 2021 May; 31(5):385-396. PubMed ID: 33678513
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy.
Finanger E; Vandenborne K; Finkel RS; Lee Sweeney H; Tennekoon G; Yum S; Mancini M; Bista P; Nichols A; Liu H; Fretzen A; Donovan JM
J Neuromuscul Dis; 2019; 6(1):43-54. PubMed ID: 30452422
[TBL] [Abstract][Full Text] [Related]
5. A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.
Donovan JM; Zimmer M; Offman E; Grant T; Jirousek M
J Clin Pharmacol; 2017 May; 57(5):627-639. PubMed ID: 28074489
[TBL] [Abstract][Full Text] [Related]
6. Potential therapeutic impact of omega-3 long chain-polyunsaturated fatty acids on inflammation markers in Duchenne muscular dystrophy: A double-blind, controlled randomized trial.
Rodríguez-Cruz M; Cruz-Guzmán ODR; Almeida-Becerril T; Solís-Serna AD; Atilano-Miguel S; Sánchez-González JR; Barbosa-Cortés L; Ruíz-Cruz ED; Huicochea JC; Cárdenas-Conejo A; Escobar-Cedillo RE; Yam-Ontiveros CA; Ricárdez-Marcial EF
Clin Nutr; 2018 Dec; 37(6 Pt A):1840-1851. PubMed ID: 28987470
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
[TBL] [Abstract][Full Text] [Related]
8. Factor Analysis of Patients Who Find Tablets or Capsules Difficult to Swallow Due to Their Large Size: Using the Personal Health Record Infrastructure of Electronic Medication Notebooks.
Asano M; Imai S; Shimizu Y; Kizaki H; Ito Y; Tsuchiya M; Kuriyama R; Yoshida N; Shimada M; Sando T; Ishijima T; Hori S
J Med Internet Res; 2024 Apr; 26():e54645. PubMed ID: 38657229
[TBL] [Abstract][Full Text] [Related]
9. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R;
Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250
[TBL] [Abstract][Full Text] [Related]
10. Oral muscles are progressively affected in Duchenne muscular dystrophy: implications for dysphagia treatment.
van den Engel-Hoek L; Erasmus CE; Hendriks JC; Geurts AC; Klein WM; Pillen S; Sie LT; de Swart BJ; de Groot IJ
J Neurol; 2013 May; 260(5):1295-303. PubMed ID: 23263593
[TBL] [Abstract][Full Text] [Related]
11. Dysphagia in Duchenne muscular dystrophy assessed objectively by surface electromyography.
Archer SK; Garrod R; Hart N; Miller S
Dysphagia; 2013 Jun; 28(2):188-98. PubMed ID: 23179024
[TBL] [Abstract][Full Text] [Related]
12. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
[TBL] [Abstract][Full Text] [Related]
13. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.
Campbell C; McMillan HJ; Mah JK; Tarnopolsky M; Selby K; McClure T; Wilson DM; Sherman ML; Escolar D; Attie KM
Muscle Nerve; 2017 Apr; 55(4):458-464. PubMed ID: 27462804
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
[TBL] [Abstract][Full Text] [Related]
15. In situ coating makes it easier for children to swallow and tolerate tablets and capsules.
El Edelbi R; Eksborg S; Lindemalm S
Acta Paediatr; 2015 Sep; 104(9):956-61. PubMed ID: 25982837
[TBL] [Abstract][Full Text] [Related]
16. Tongue pressure during swallowing is decreased in patients with Duchenne muscular dystrophy.
Hamanaka-Kondoh S; Kondoh J; Tamine K; Hori K; Fujiwara S; Maeda Y; Matsumura T; Yasui K; Fujimura H; Sakoda S; Ono T
Neuromuscul Disord; 2014 Jun; 24(6):474-81. PubMed ID: 24684858
[TBL] [Abstract][Full Text] [Related]
17. Evidence of muscle loss delay and improvement of hyperinsulinemia and insulin resistance in Duchenne muscular dystrophy supplemented with omega-3 fatty acids: A randomized study.
Rodríguez-Cruz M; Atilano-Miguel S; Barbosa-Cortés L; Bernabé-García M; Almeida-Becerril T; Cárdenas-Conejo A; Del Rocío Cruz-Guzmán O; Maldonado-Hernández J
Clin Nutr; 2019 Oct; 38(5):2087-2097. PubMed ID: 30420291
[TBL] [Abstract][Full Text] [Related]
18. Swallowing difficulties in Duchenne muscular dystrophy: indications for feeding assessment and outcome of videofluroscopic swallow studies.
Aloysius A; Born P; Kinali M; Davis T; Pane M; Mercuri E
Eur J Paediatr Neurol; 2008 May; 12(3):239-45. PubMed ID: 18055233
[TBL] [Abstract][Full Text] [Related]
19. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
